Kevin P. Daly | Medical Services
Specialties
Programs & Services
- Cardiology
- Cardiology Outpatient Services
- Cardiomyopathy Program
- Heart Center
- Ventricular Assist Device (VAD) Program
Languages
- English
Kevin P. Daly | Education
Undergraduate School
Biochemical Sciences
Harvard University
2000, Boston, MA
Medical School
Columbia University College of Physicians & Surgeons
2004, New York, NY
Internship
Children’s Hospital at Montefiore
2005, Bronx, NY
Residency
Pediatrics
Children’s Hospital at Montefiore
2007, Bronx, NY
Fellowship
Pediatric Cardiology
Boston Children's Hospital
2009, Boston, MA
Fellowship
Chief Fellow, Pediatric Cardiology
Boston Children's Hospital
2010, Boston, MA
Fellowship
Pediatric Cardiology; Heart Failure; Transplantation Senior Fellow
Boston Children's Hospital
2011, Boston, MA
Kevin P. Daly | Certifications
- American Board of Pediatrics (Cardiology)
- American Board of Pediatrics (General)
Kevin P. Daly | Professional History
I am a pediatric cardiologist at Boston Children’s Hospital specializing in Heart Failure & Transplantation. My clinical work is focused on the evaluation and management of children with advanced heart failure and those requiring mechanical circulatory support and/or heart transplantation. I am also a translational researcher focused on the development of biomarkers and novel imaging technologies which will allow for non-invasive diagnosis of cardiac allograft vasculopathy (CAV).
I am a clinical expert in the diagnosis and management of the highly sensitized pediatric heart transplant patient and those who develop antibody mediated rejection. I have published our center’s experience with peri-operative desensitization for crossmatch positive heart transplantation and utilized eculizumab (a terminal complement inhibitor) and bortezomib (a proteasome inhibitor) for the treatment of antibody mediated rejection. I am the only transplant physician in our group to perform intracardiac hemodynamics, endomyocardial biopsies, and coronary angiography in transplant patients and have expertise in the diagnosis of CAV.
I have demonstrated that VEGF-A can be used to stratify risk for development CAV in children after heart transplantation. We are planning a prospective study to determine if VEGF-A testing can safely reduce the frequency of invasive coronary angiography procedures in pediatric heart transplant recipients. In addition, I am leading a multi-center collaboration to design and perform the first randomized control trial of maintenance immunosuppression in pediatric heart transplantation. We expect this trial will support the first FDA approved indication for maintenance immunosuppression in pediatric heart transplantation.